On the other hand, in the study conducted by Braun, as well as in the one conducted by Fouache, no statistically significant difference was identified in new-onset IBD between patients treated with placebo and those treated with anti-TNF agents [2,24]. The gene discussed is TNF; the disease is inflammatory bowel disease.